Quick Facts

• Acute Pain Management: Indicated for providing symptomatic relief of mild-to-moderate short-term pain.
• Joint Conditions: Used to manage the signs and symptoms associated with osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis.
• Inflammatory Symptoms: Assists in reducing inflammation, joint swelling, and stiffness linked to arthritis.
• Other Uses: May provide relief for acute gout attacks and menstrual pain (primary dysmenorrhea).

---

What Panamor Treats: Main Uses and Benefits

Panamor, containing diclofenac, is a therapeutic agent used for the symptomatic management of various pain and inflammatory conditions. The medication helps address the signs and discomfort associated with several common conditions, primarily those involving the musculoskeletal system.

It is indicated for the temporary relief of mild-to-moderate acute pain states. This includes discomfort following certain procedures or injuries. Panamor is also utilized for the long-term management of chronic arthritic conditions. This treatment assists in mitigating the characteristic signs and symptoms of rheumatoid arthritis and osteoarthritis, which involve joint pain, swelling, and stiffness. Furthermore, it is a treatment option for the signs and symptoms of ankylosing spondylitis, a form of arthritis that affects the spine.

Additional therapeutic applications include providing symptomatic relief for painful menstrual periods (primary dysmenorrhea) and the management of acute attacks of gout, which involve sudden, intense episodes of joint pain and swelling. The use of this medicine involves assessment by a healthcare professional.

Official Eligibility Status for Panamor (Diclofenac)

Panamor's eligibility profile, derived from regulatory documents, defines specific populations who are prohibited from use and others who require caution.

Eligibility Classification	Population Restriction
Absolutely Contraindicated	Patients with known hypersensitivity to diclofenac, aspirin, or any other NSAID; history of NSAID-triggered asthma or allergic reactions; active GI bleeding/ulceration; severe hepatic or renal failure; or those undergoing CABG surgery [FDA, EMA].
Use Not Recommended	Systemic forms are not recommended for children under 14 years [HPRA]. Contraindicated in the third trimester of pregnancy (after 30 weeks gestation) and use should be avoided from 20 weeks [FDA].

Condition-Specific Rules: Use requires caution in patients with mild-to-moderate renal or hepatic impairment, specific cardiovascular risk factors (e.g., hypertension), or inflammatory conditions like Crohn’s disease [HPRA, GOV.UK]. The General Adult Population is the standard eligible group for labeled indications, while older adults are advised to use the lowest effective dose due to increased risk of serious gastrointestinal events [FDA].

Panamor (Diclofenac) interacts with several medicinal products and substances, as formally documented in regulatory labels, primarily through pharmacokinetic and pharmacodynamic mechanisms. The strongest restriction is the contraindication of use following Coronary Artery Bypass Graft (CABG) surgery and with other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of aspirin, due to heightened risk of serious adverse events.

A key pharmacokinetic interaction involves strong CYP2C9 inhibitors like Voriconazole, which is documented to significantly increase the plasma concentration (AUC/Cmax) of Diclofenac. Diclofenac itself is noted to increase the serum concentrations of co-administered agents like Lithium, Digoxin, and Methotrexate, requiring regulatory awareness.

From a pharmacodynamic standpoint, co-administration with blood thinners (Anticoagulants, Antiplatelet agents), SSRIs, or Oral Corticosteroids is officially associated with an amplified risk of serious gastrointestinal bleeding. Furthermore, Diclofenac can reduce the therapeutic efficacy of Diuretics and ACE Inhibitors/ARBs. Regulatory documents note this renal function risk is increased in the elderly, volume-depleted, or renal-impaired populations. Finally, consumption of alcohol and use of Ginkgo Biloba are officially listed as substances that increase the bleeding risk. Certain oral formulations require administration on an empty stomach due to documented reductions in effectiveness when taken with food.

The action of Panamor (Diclofenac) is defined by a multi-faceted pharmacodynamic mechanism affecting both peripheral signaling and central nervous system pathways.

Its primary domain involves the competitive inhibition of the Cyclooxygenase-2 (COX-2) enzyme. This molecular action blocks the conversion of arachidonic acid into Prostaglandin E2 (PGE2) and other inflammatory mediators. Suppression of PGE2 formation alters the pathway responsible for generating these mediators. This blockade results in the physiological consequence of decreased localized vasodilation and capillary permeability.

Extending beyond peripheral COX blockade, the mechanism involves engagement with pathways in the central nervous system and at peripheral nerve terminals. It prevents PGE2 from sensitizing nociceptors and additionally modulates pain transmission pathways, including the L-arginine/Nitric Oxide pathway, and activates ATP-sensitive potassium channels (KATP). These distinct actions result in the modulation of nociceptive input, establishing a physiological state that combines the alteration of central pain transmission with the reduction of peripheral mediators.

The administration of Panamor, which contains diclofenac, is characterized by protocols that emphasize using the lowest effective dose for the shortest possible duration consistent with treatment goals. The medicine is available for Oral, Rectal, Topical, and Parenteral (Intramuscular/Intravenous) routes, each with specific procedural rules.

Oral and Topical Administration

For oral forms, such as delayed-release tablets, the typical adult daily dose ranges from 100 mg to 200 mg, administered in divided doses or, for extended-release formulations, once daily. Enteric-coated tablets must be swallowed whole with liquid and should not be crushed or chewed. Some specialized oral powder forms require mixing with a small amount of water and must be consumed immediately on an empty stomach. Topical preparations are applied directly to the skin, with dosing measured precisely for specific joint groups (e.g., upper or lower extremities).

Parenteral Administration

The parenteral route is intended for acute use only, with the clinical restriction that Intramuscular (IM) or Intravenous (IV) administration must not exceed two days. The standard dose is 75 mg, which may be repeated after a 4-to-6-hour interval, with a maximum daily limit of 150 mg. IV administration requires the 75 mg solution to be diluted and buffered with sodium chloride or glucose solution prior to infusion; it must be administered slowly as an infusion, and is strictly forbidden as a bolus injection.

General Principles

If a dose is missed, it should be taken as soon as the patient remembers, unless it is nearly time for the next scheduled dose, in which case the missed dose must be skipped. Patients should never double the dose to compensate. The lowest effective dosage should be used in older adults, and use in the pediatric population is subject to specific formulation and age restrictions.

Research evidence / Overview of Studies for Panamor (Diclofenac)

---

Evidence for Use in Chronic Inflammatory Conditions

Research concerning the systemic use of Diclofenac was studied for conditions characterized by fluctuating or episodic manifestations, such as osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. This section describes the functional and symptomatic outcomes that researchers have measured over the defined study periods. Studies have utilized Randomized Controlled Trials (RCTs) to compare the medication against a non-active substance or other standard options. Researchers included adult populations with established diagnoses, often focusing on outcomes related to physical discomfort, joint stiffness, and outcomes reflecting daily functioning or activity level.

These trials, typically lasting 6 to 12 weeks, describe patterns observed in the studies related to changes in patient-reported pain scores and functional measurements, such as those used to examine daily functioning or activity level. The evidence contributes to understanding symptom patterns and is often evaluated in large Randomized Controlled Trials. Research is ongoing, and the existing evidence provides limited information for long-term outcomes, particularly concerning the persistence of reported changes beyond the initial few months. Findings primarily describe symptom patterns observed in the studies rather than exploring fundamental changes in the progression of the underlying disease.

---

Evidence for Relief of Acute Pain States

This part outlines the research base for the short-term use of Diclofenac, covering conditions such as post-operative pain, soft tissue injuries, primary dysmenorrhea, and acute gout flares. This section describes the design of short-duration clinical trials and what specific pain intensity and outcome measurements were collected by investigators. Research has primarily relied on short-term RCTs and subsequent Meta-Analyses. These studies focused on healthy adults and often monitored outcomes describing episodic or acute changes, such as the total pain change reported by patients and the time it took for them to report their first perceptible change.

The short follow-up durations in most of these trials suggest that results apply only to the populations studied during the immediate, acute phase. Long-term effects for these indications are not fully established, as the research scenario involved temporary physiological imbalance rather than chronic use.

---

Evidence for Localized (Topical) Use

This area focuses on the evidence from trials exploring topical application and those concerning systemic (oral) administration for conditions such as localized osteoarthritis and acute musculoskeletal strains. Investigators performed RCTs comparing topical Diclofenac formulations (gels or solutions) against a non-active vehicle. Studies monitored changes measured during the study period, typically over 6 to 12 weeks, focusing on the affected joint. Research also examines the concentration of the active ingredient delivered to the underlying joint tissue, as observed in studies of topical permeation.

The evidence is limited regarding direct, head-to-head comparisons between the various topical formulations for chronic conditions. Additionally, there is limited information for long-term outcomes regarding the localized forms used for chronic conditions.

Key Studies & References

1. Diclofenac: MedlinePlus Drug Information
2. Efficacy and safety of diclofenac in osteoarthritis: systematic review and meta-analysis of randomized controlled trials

Common questions about Panamor (FAQ)

---

Q: Can Panamor be taken long-term for a chronic condition?

A: Official prescribing information emphasizes that this medicine is described as being used at the lowest effective dose for the shortest possible duration. This guidance is included to minimize the potential for serious cardiovascular and gastrointestinal risks. The appropriate length of treatment for any chronic condition is determined by a healthcare professional based on an individual's specific health and risk profile.

Q: Are there any common foods or drinks that should be avoided while taking Panamor?

A: Official guidance states that certain oral forms are typically instructed to be taken on an empty stomach to ensure proper absorption and effectiveness. Additionally, regulatory documents note that consuming alcohol while using this medicine increases the risk of gastrointestinal bleeding. Consultation of the specific administration instructions for the formulation is necessary.

Q: Is it okay to take Panamor with vitamins or herbal supplements?

A: Regulatory warnings note that combining this medicine with certain herbal products, such as Ginkgo Biloba, can potentially increase the risk of bleeding. Due to the possibility of interactions that could affect safety or effectiveness, regulatory documents emphasize the importance of communicating with a healthcare professional about all vitamins and supplements being used.

Q: What types of allergic reactions are associated with Panamor?

A: The official regulatory label describes potential serious hypersensitivity reactions, which include anaphylaxis and swelling known as angioedema. The medicine is formally contraindicated in patients who have a history of asthma, hives, or other allergic-type reactions after taking aspirin or other Nonsteroidal Anti-inflammatory Drugs (NSAIDs).

Q: Does Panamor change how blood clotting works?

A: The active ingredient in this medicine, Diclofenac, is officially described as having an inhibitory effect on platelet function, which are the components of blood responsible for clotting. Regulatory warnings note that using it with blood-thinning agents (anticoagulants) increases the risk of serious gastrointestinal bleeding.

Q: Can people with high blood pressure use Panamor?

A: Official documents indicate the use of caution when this medicine is administered to patients with uncontrolled high blood pressure (hypertension). NSAIDs can potentially cause high blood pressure to begin or worsen pre-existing hypertension. It is also noted in regulatory information that the medicine may reduce the effectiveness of some blood pressure medications.

Q: Is Panamor safe for teenagers?

A: Systemic use (e.g., oral tablets) is typically restricted to patients who are 18 years of age and older for most labeled conditions. Regulatory documents indicate that use for patients older than 14 years may be described for certain specific juvenile conditions, often requiring specific formulations and dose calculations.

Q: Does taking Panamor with food reduce side effects?

A: While official documentation does not explicitly guarantee a reduction in all side effects, taking the medicine with food or milk may be recommended to help minimize potential gastrointestinal upset. Gastrointestinal disorders are frequently listed as common adverse reactions in the official safety information.

Q: Can Panamor be crushed or split if it is a tablet?

A: Regulatory labeling strictly requires that enteric-coated or extended-release tablets are required to be swallowed whole and not crushed or chewed. This requirement is essential for protecting the stomach or ensuring the medicine is released correctly over time. Alteration of the tablet is not recommended unless the official administration instructions explicitly permit it.

Q: Can Panamor be taken at the same time as cold or flu medicines?

A: Official regulatory guidance indicates that use of this medicine is not recommended at the same time as other Nonsteroidal Anti-inflammatory Drugs (NSAIDs), including analgesic doses of aspirin. Combining these medicines significantly increases the risk of serious adverse events. Since many common cold and flu medicines contain other NSAIDs, review of their ingredients is important.

Q: Do people typically experience stomach upset right away, or after long-term use?

A: Official regulatory labels state that common gastrointestinal side effects, like nausea and abdominal pain, can occur frequently and may be experienced relatively early in treatment. However, serious gastrointestinal events, such as bleeding or ulceration, are documented to occur at any time during therapy, sometimes without obvious warning signs.

Q: What is the expected maximum duration of treatment with Panamor?

A: For parenteral (injection) administration, official guidelines specify that use is limited to a period not exceeding two days. For the more common oral and topical forms, regulatory guidance emphasizes the need for the lowest effective dose to be used for the shortest possible duration consistent with the treatment goal.

Q: Why is Panamor sometimes described as a 'selective' medicine?

A: This medicine is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID) which is formally described as a competitive inhibitor of the Cyclooxygenase enzymes. Official mechanism of action information indicates that it demonstrates a degree of preferential inhibition of the COX-2 enzyme, which is involved in inflammation, compared to the COX-1 enzyme.

Q: How long does it usually take for Panamor to start working?

A: Official documents describing the medicine's pharmacokinetics indicate that the active ingredient reaches its peak concentration in the bloodstream for immediate-release oral forms typically within 1 to 4 hours after administration. This pharmacokinetic measurement is related to the time it takes for the medicine's effects to begin.

Q: What happens if I stop taking Panamor suddenly?

A: Regulatory documents do not list specific withdrawal symptoms associated with stopping this medicine. For short-term use, cessation typically involves the gradual and eventual resolution of the medicine's therapeutic effects.

Q: Does Panamor cause drowsiness or affect my ability to drive?

A: The official regulatory label lists potential central nervous system side effects including dizziness and drowsiness. Because of these potential effects, regulatory guidance notes the importance of being aware of one's reaction to the medicine before engaging in activities that require alertness, such as driving or operating machinery.

Q: Is Panamor a controlled substance?

A: Regulatory scheduling information confirms that the active ingredient in this medicine is not classified as a controlled substance. It is not scheduled under the U.S. Drug Enforcement Administration (DEA) or equivalent international regulatory systems.

Q: Is there a generic version of Panamor available?

A: Official drug listings confirm that the active ingredient, Diclofenac, is available in multiple generic formulations from various manufacturers. These generic versions became available after the brand-name patent exclusivity period expired.

Q: Is Panamor known to interact with birth control pills?

A: Regulatory documents that detail interactions do not typically list hormonal contraceptives (birth control pills) as a major restriction. However, official guidance emphasizes the necessity of a professional review of all concurrent medicines, including hormonal birth control, before starting or stopping this medicine.

Q: How quickly does the effect of Panamor wear off after taking it?

A: The official pharmacokinetics section describes the medicine's half-life—the time required for the amount of active drug in the body to be reduced by half—as approximately 1 to 2 hours for the parent compound. This metric indicates how quickly the medicine is eliminated from the system.

Q: What if Panamor doesn't seem to be helping my condition?

A: Regulatory guidance emphasizes that this medicine is intended for symptomatic relief of pain and inflammation. If the expected therapeutic effects are not being achieved, official information highlights the necessity of consulting a healthcare professional to review the diagnosis and treatment plan.

Q: Can Panamor affect mood or cause anxiety?

A: Official regulatory documents list potential central nervous system side effects in the adverse reactions section. Mood changes, including rare instances of anxiety and depression, are noted among the post-marketing reports for the active ingredient.

Q: What is the official safety classification of Panamor?

A: Under the FDA's Pregnancy and Lactation Labeling Rule (PLLR), this medicine is specifically classified as contraindicated for use in pregnant women starting at 30 weeks gestation. Official documents also advise avoiding its use from 20 weeks gestation onward due to potential fetal risks.

Q: Can nursing mothers take Panamor?

A: Regulatory documents describe how the active ingredient is excreted in breast milk in small amounts. For this reason, official guidance states that use by nursing mothers is generally not recommended unless a healthcare professional determines that the benefit outweighs the potential risks to the infant.

Q: Are there any studies comparing Panamor use in different age groups?

A: The official research evidence sections in regulatory documents often detail clinical trials that include sub-analyses or separate studies for different age cohorts. This is done to define the appropriate safety profiles and effective dosing for groups such as older adults versus younger adult populations.

Q: What kind of monitoring is needed while on Panamor long-term?

A: For patients receiving long-term treatment, periodic monitoring is noted as necessary in official regulatory documents to detect potential issues. Monitoring typically includes checking renal (kidney) function, hepatic (liver) function, and blood counts due to the associated risks of long-term NSAID use.

Q: Is the research evidence for Panamor limited or extensive?

A: The research base for this medicine is considered extensive, as indicated by the multiple sections in official regulatory documents that detail numerous Randomized Controlled Trials (RCTs) and Meta-Analyses. This volume of evidence has been formally reviewed by regulatory agencies across various indications.

Q: Is Panamor known to cause weight gain or loss?

A: Official regulatory adverse reaction lists note that fluid retention and edema (swelling) can occur, which may be associated with weight gain. Weight changes (either an increase or decrease) are also listed in the regulatory documents as a potential but less frequently reported side effect.

Q: What if I have diabetes; can I still use Panamor?

A: While official documents do not list diabetes as a formal contraindication, regulatory guidance indicates the need for caution for patients with conditions that may affect cardiovascular or renal function. A professional review of a patient's complete medication list and health status is recommended before use.

Q: Are there any required tests before starting Panamor?

A: Regulatory documents note that healthcare professionals may consider pre-treatment testing for some individuals. Testing, such as renal function tests or blood cell counts, is typically considered for patients with pre-existing risk factors or before beginning long-term therapy.

Q: Does Panamor affect blood sugar levels?

A: Official adverse reactions lists note that changes in blood sugar levels have been reported for the active ingredient. These changes include rare cases of both hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar).

Q: Where can I find the official regulatory information sheet for Panamor?

A: The official, full regulatory information and prescribing details are available on public government-run drug databases. These sources include DailyMed (published by the FDA) and the European Medicines Agency (EMA) website, where the full regulatory documents are published.

Q: What should I do if I notice unusual bruising while taking Panamor?

A: Regulatory guidance indicates that unusual bruising or bleeding is a potential sign of a serious adverse event related to increased bleeding risk. Official advice highlights that prompt medical attention may be necessary if patients observe any signs of bleeding or bruising.

The storage and disposal of Panamor, a diclofenac-containing medicine, must adhere strictly to the conditions detailed in the official regulatory labeling to ensure product stability and environmental safety.

Detail	Official Regulatory Requirement
Labeled Storage Temperature	Store at a temperature at or below 25°C (for common forms).
Light/Moisture Protection	Keep in the original container/carton and do not store in a bathroom (high humidity).
Stability Warning	Do not use after the expiry date stated on the label. Suppositories must not be divided for storage, as this may compromise active medicine distribution.
Child-Protection	Keep out of the sight and reach of children (mandatory safety statement).
Official Disposal Rules	Do not dispose of unused medicine in drains or wastewater (e.g., toilets).
Disposal Method	Unused or expired medicine must be returned to a pharmacist for proper, regulated disposal.

This structure ensures the medicine is protected from unsuitable environments and is disposed of in accordance with official pharmaceutical and environmental waste protocols.